vs
Evolus, Inc.（EOLS）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是Evolus, Inc.的1.0倍（$75.5M vs $73.1M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 6.7%），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 4.6%）
Evolus是一家聚焦医疗美容赛道的企业，主营非手术类美容治疗产品的研发与商业化，核心产品为可改善中度至重度皱眉纹的处方神经调节剂，服务覆盖北美、欧洲及亚太核心市场的医美机构与消费者。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
EOLS vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.0倍
$73.1M
营收增速更快
PBYI
高出21.0%
6.7%
两年增速更快
PBYI
近两年复合增速
4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $73.1M | $75.5M |
| 净利润 | $-10.7M | — |
| 毛利率 | 66.9% | 69.3% |
| 营业利润率 | 23.8% | 22.7% |
| 净利率 | -14.6% | — |
| 营收同比 | 6.7% | 27.7% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.16 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EOLSPBYI
| Q1 26 | $73.1M | — | ||
| Q4 25 | $90.3M | $75.5M | ||
| Q3 25 | $69.0M | $54.5M | ||
| Q2 25 | $69.4M | $52.4M | ||
| Q1 25 | $68.5M | $46.0M | ||
| Q4 24 | $78.9M | $59.1M | ||
| Q3 24 | $61.1M | $80.5M | ||
| Q2 24 | $66.9M | $47.1M |
净利润EOLSPBYI
| Q1 26 | $-10.7M | — | ||
| Q4 25 | $130.0K | — | ||
| Q3 25 | $-15.7M | $8.8M | ||
| Q2 25 | $-17.1M | $5.9M | ||
| Q1 25 | $-18.9M | $3.0M | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | $-19.2M | $20.3M | ||
| Q2 24 | $-11.3M | $-4.5M |
毛利率EOLSPBYI
| Q1 26 | 66.9% | — | ||
| Q4 25 | 65.7% | 69.3% | ||
| Q3 25 | 66.5% | 77.7% | ||
| Q2 25 | 65.3% | 76.5% | ||
| Q1 25 | 68.1% | 77.1% | ||
| Q4 24 | 66.7% | 76.4% | ||
| Q3 24 | 68.9% | 63.9% | ||
| Q2 24 | 70.3% | 77.4% |
营业利润率EOLSPBYI
| Q1 26 | 23.8% | — | ||
| Q4 25 | 4.7% | 22.7% | ||
| Q3 25 | -16.7% | 17.6% | ||
| Q2 25 | -14.7% | 12.7% | ||
| Q1 25 | -22.1% | 8.7% | ||
| Q4 24 | -2.9% | 22.6% | ||
| Q3 24 | -25.3% | 27.4% | ||
| Q2 24 | -11.5% | -4.6% |
净利率EOLSPBYI
| Q1 26 | -14.6% | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | -22.8% | 16.2% | ||
| Q2 25 | -24.7% | 11.2% | ||
| Q1 25 | -27.6% | 6.5% | ||
| Q4 24 | -8.6% | — | ||
| Q3 24 | -31.4% | 25.2% | ||
| Q2 24 | -17.0% | -9.6% |
每股收益（稀释后）EOLSPBYI
| Q1 26 | $-0.16 | — | ||
| Q4 25 | $0.01 | $0.26 | ||
| Q3 25 | $-0.24 | $0.17 | ||
| Q2 25 | $-0.27 | $0.12 | ||
| Q1 25 | $-0.30 | $0.06 | ||
| Q4 24 | $-0.11 | $0.40 | ||
| Q3 24 | $-0.30 | $0.41 | ||
| Q2 24 | $-0.18 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.8M | $97.5M |
| 总债务越低越好 | $156.4M | $22.7M |
| 股东权益账面价值 | — | $130.3M |
| 总资产 | $220.6M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资EOLSPBYI
| Q1 26 | $49.8M | — | ||
| Q4 25 | $53.8M | $97.5M | ||
| Q3 25 | $43.5M | $94.4M | ||
| Q2 25 | $61.7M | $96.0M | ||
| Q1 25 | $67.9M | $93.2M | ||
| Q4 24 | $87.0M | $101.0M | ||
| Q3 24 | $85.0M | $96.7M | ||
| Q2 24 | $93.7M | $96.8M |
总债务EOLSPBYI
| Q1 26 | $156.4M | — | ||
| Q4 25 | $146.1M | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | $121.8M | $56.7M | ||
| Q4 24 | $121.5M | $68.0M | ||
| Q3 24 | $121.2M | $79.3M | ||
| Q2 24 | $120.9M | $90.7M |
股东权益EOLSPBYI
| Q1 26 | — | — | ||
| Q4 25 | $-23.1M | $130.3M | ||
| Q3 25 | $-28.8M | $115.3M | ||
| Q2 25 | $-18.7M | $104.7M | ||
| Q1 25 | $-6.6M | $97.1M | ||
| Q4 24 | $5.5M | $92.1M | ||
| Q3 24 | $5.9M | $71.1M | ||
| Q2 24 | $19.3M | $48.5M |
总资产EOLSPBYI
| Q1 26 | $220.6M | — | ||
| Q4 25 | $225.9M | $216.3M | ||
| Q3 25 | $219.0M | $202.9M | ||
| Q2 25 | $228.8M | $194.9M | ||
| Q1 25 | $213.4M | $196.2M | ||
| Q4 24 | $232.6M | $213.3M | ||
| Q3 24 | $229.6M | $220.7M | ||
| Q2 24 | $233.8M | $205.0M |
负债/权益比EOLSPBYI
| Q1 26 | — | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | 22.00× | 0.74× | ||
| Q3 24 | 20.58× | 1.12× | ||
| Q2 24 | 6.26× | 1.87× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $14.4M |
| 自由现金流经营现金流 - 资本支出 | — | $14.4M |
| 自由现金流率自由现金流/营收 | — | 19.1% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $41.7M |
8季度趋势，按日历期对齐
经营现金流EOLSPBYI
| Q1 26 | — | — | ||
| Q4 25 | $12.8M | $14.4M | ||
| Q3 25 | $-14.7M | $9.7M | ||
| Q2 25 | $-24.8M | $14.1M | ||
| Q1 25 | $-15.6M | $3.6M | ||
| Q4 24 | $4.8M | $15.6M | ||
| Q3 24 | $-5.7M | $11.0M | ||
| Q2 24 | $-6.5M | $1.0M |
自由现金流EOLSPBYI
| Q1 26 | — | — | ||
| Q4 25 | $11.3M | $14.4M | ||
| Q3 25 | $-15.6M | $9.7M | ||
| Q2 25 | $-25.5M | $14.1M | ||
| Q1 25 | $-16.0M | $3.6M | ||
| Q4 24 | $4.4M | $15.6M | ||
| Q3 24 | $-6.0M | $11.0M | ||
| Q2 24 | $-6.9M | $1.0M |
自由现金流率EOLSPBYI
| Q1 26 | — | — | ||
| Q4 25 | 12.6% | 19.1% | ||
| Q3 25 | -22.7% | 17.7% | ||
| Q2 25 | -36.7% | 26.8% | ||
| Q1 25 | -23.3% | 7.7% | ||
| Q4 24 | 5.5% | 26.4% | ||
| Q3 24 | -9.9% | 13.7% | ||
| Q2 24 | -10.4% | 2.1% |
资本支出强度EOLSPBYI
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | 0.0% | ||
| Q3 25 | 1.4% | 0.0% | ||
| Q2 25 | 1.0% | 0.0% | ||
| Q1 25 | 0.5% | 0.1% | ||
| Q4 24 | 0.6% | 0.0% | ||
| Q3 24 | 0.5% | 0.0% | ||
| Q2 24 | 0.7% | 0.0% |
现金转化率EOLSPBYI
| Q1 26 | — | — | ||
| Q4 25 | 98.67× | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EOLS
| Product revenue, net | $72.7M | 99% |
| Service revenue | $390.0K | 1% |
PBYI
暂无分部数据
